top of page
Medical Checkup

EXHALE-2

Trial Enrolment Status

OPEN

Disease Under Study

ASTHMA

Duration

~52 Weeks

About the Trial

A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, and tolerability of dexpramipexole administered orally for 52 weeks in participants with severe eosinophilic asthma (EXHALE-2)

Mechanism of Action:

​

Duration of Study

~52 Weeks

Phase

3

Principal Investigator

Dr. George Philteos

Sub-Investigator

Dr. Anushya Chelvanathan

Study Coordinator

Carrie Harrison/Hannah Harrison

Dr. Philteos and Associates | Dynamic Drug Advancement Limited

Address:

Hours:

601 Harwood Avenue South, Suite 201

Ajax, Ontario L1S 2J5

M-F:

9:00am - 5:00pm

Closed on statutory holidays

Main Office Phone: 

 

 

Main Office Fax:   

Clinical Trial Phone:

Clinical Trial Fax: 

Dr. Philteos: (905) 427-1419

Dr. Chelvanathan: (905) 239 0225

Dr. O'Loghlen: (905) 239 0221

(905) 427-0346

(365) 885-9086

(905) 239-2399

©2022 by Dynamic Drug Advancement. Proudly created with Wix.com

bottom of page